Author information 1Gastroenterology Department, Complexo Hospitalario Universitario de Santiago de Compostela and Santiago de Compostela Health Research Institute, Santiago de Compostela, Spain. 2Gastroenterology Department, Hospital Universitario de Galdakao and Biocruces Bizkaia Health Research Institute, Galdakao, Spain. 3Gastroenterology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain. 4Gastroenterology Department, Hospital Clínic i Provincial, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. 5Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain. 6Gastroenterology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain. 7Gastroenterology Department, Hospital Regional Universitario de Málaga, Málaga, Spain. 8Gastroenterology Department, Hospital Universitario Central de Asturias, Oviedo, Spain. 9Gastroenterology Department, Hospital Universitario Reina Sofía, IMIBIC, Universidad de Córdoba, Córdoba, Spain. 10Gastroenterology Department, Hospital General de Alicante and Instituto de Investigación Sanitaria y Biomédica de Alicante ISABIAL, Alicante, Spain. 11Gastroenterology Department, Complexo Hospitalario Universitario de A Coruña, A Coruña, Spain. 12Gastroenterology Department, Hospital Universitario Donostia and Biodonostia Health Research Institute, San Sebastián- Gipuzkoa, Spain. 13Gastroenterology Department, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain. 14Gastroenterology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain. 15Gastroenterology Department, Complexo Hospitalario Universitario de Pontevedra, Pontevedra, Spain. 16Gastroenterology Department, Hospital Santa Creu i Sant Pau, Barcelona, Spain. 17Gastroenterology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain. 18Gastroenterology Department, Hospital Universitario 12 de Octubre, Madrid, Spain. 19Gastroenterology Department, Hospital Universitario de Canarias, Tenerife, Spain. 20Gastroenterology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain. 21Gastroenterology Department, Hospital del Mar, Barcelona, Spain. 22Gastroenterology Department, Hospital Josep Trueta, Girona, Spain. 23Gastroenterology Department, Hospital Universitario La Paz, Madrid, Spain. 24Gastroenterology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain. 25Gastroenterology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain. 26Gastroenterology Department, Hospital Universitario de Álava, Vitoria, Spain. 27Gastroenterology Department, Hospital Universitario de Navarra, Navarra, Spain. 28Gastroenterology Department, Hospital Doctor Peset, Valencia, Spain. 29Gastroenterology Department, Hospital Universitari Parc Taulí, Sabadell, Spain. 30Gastroenterology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa and Universidad Autónoma de Madrid, Madrid, Spain. 31Gastroenterology Department, Hospital Universitari Mútua Terrasa, Barcelona, Spain. 32Gastroenterology Department, Lanzarote, Spain. Abstract Background: Limited data are available on the outcome of inflammatory bowel disease (IBD) in patients with solid organ transplantation (SOT). We describe the natural history of pre-existing IBD and de novo IBD after SOT. Methods: This was a retrospective, multicenter study that included patients with pre-existing IBD at the time of SOT and patients with de novo IBD after SOT. The primary outcome was IBD progression, defined by escalation of medical treatment, surgical therapy, or hospitalization due to refractory IBD. Risk factors were identified using multivariate Cox proportional hazard analysis. Results: A total of 177 patients (106 pre-existing IBD and 71 de novo IBD) were included. Most patients with pre-existing IBD (92.5%) were in remission before SOT. During follow-up, 32% of patients with pre-existing IBD had disease progression, with a median time between SOT and IBD progression of 2.2 (interquartile range, 1.3-4.6) years. In the de novo cohort, 55% of patients had disease progression with a median time to flare of 1.9 (interquartile range, 0.8-3.9) years after diagnosis. In the pre-existing IBD cohort, active IBD at the time of SOT (hazard ratio, 1.80; 95% confidence interval, 1.14-2.84; P = .012) and the presence of extraintestinal manifestations (hazard ratio, 3.10; 95% confidence interval, 1.47-6.54; P = .003) were predictive factors for IBD progression. Conclusions: One-third of patients with pre-existing IBD and about half of patients with de novo IBD have disease progression after SOT. Active IBD at the time of SOT and the presence of extraintestinal manifestations were identified as risk factors for IBD progression. |
© Copyright 2013-2025 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only.
Use of this website is governed by the GIHF terms of use and privacy statement.